2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12B.11 ALK Positive Lifestudy

Pdf Summary

The ALK Life Study is a comprehensive global registry initiative, led by ALK Positive Inc. and involving institutions like Wayne State University and the University of Washington, aiming to map out the diagnostic and treatment pathways for patients with ALK-positive non-small cell lung cancer (NSCLC). The study intends to become the largest global real-world evidence dataset for this cancer subtype.<br /><br />Launched in 2022, the registry has enrolled approximately 1,332 patients as of mid-2024, with a target enrollment of 5,000. The average age of diagnosis among participants is 51.9 years. The patient data collected range from demographics to detailed medical histories, with ongoing updates gathered biannually through surveys. Patients partake from 71 countries, with a significant majority from North America.<br /><br />At the point of enrollment, symptoms like cough, shortness of breath, and fatigue are the most frequently reported. A majority of participants are diagnosed at stage IV of the disease. A significant finding of the study is that it takes, on average, 101 days from the first lung cancer symptoms to the commencement of ALK TKI (tyrosine kinase inhibitor) treatment, which is longer than the timelines reported in other studies. <br /><br />This extensive database aligns with existing ALK-positive NSCLC data but provides new insights by highlighting extended diagnostic timelines. The study aims to leverage these insights to pinpoint critical intervention points that could expedite diagnosis and treatment, improving patient outcomes. The study design also allows for future participant re-engagement, facilitating their involvement in forthcoming research. <br /><br />In collaboration with sponsors like Takeda Oncology, the authors acknowledge the invaluable contribution of patients and care partners in driving this important research forward.

Asset Subtitle

Ken Culver

Meta Tag

Speaker Ken Culver

Topic Metastatic NSCLC – Targeted Therapy

Keywords

ALK Life Study

global registry

ALK-positive NSCLC

real-world evidence

diagnostic pathways

treatment pathways

patient outcomes

tyrosine kinase inhibitor

diagnostic timelines

Takeda Oncology